Sagility Q1 FY27 Results: Revenue Grows 27.6% YoY, Company Reiterates Double-Digit Growth Guidance

What Happened ?

Sagility began FY27 with strong operational momentum as demand remained healthy across U.S. healthcare payers seeking cost optimisation, clinical management and AI-enabled transformation.

Growth during the quarter was primarily driven by expansion within existing client relationships, scaling of clients added during FY26 and increasing demand for higher-value healthcare services. The recently completed CareSeed acquisition further strengthened Sagility’s healthcare quality capabilities while adding new mid-market payer clients.

key details

Revenue & Profitability:

• Revenue increased 27.6% YoY to ₹1,963.5 crore.
• Organic revenue grew 27.3% YoY.
• Constant currency growth stood at 15.2%.
• Adjusted EBITDA increased 27.9% YoY.
• Adjusted PAT grew 35.1% YoY.
• Operating cash conversion remained healthy at around 70%.
• Working capital improved with DSO reducing to 80 days.

Note:

• The company maintained profitability despite annual salary revisions and statutory wage increases.

Commercial Momentum:

• Signed US$35.3 million steady-state Annual Contract Value (ACV) during the quarter.
• Won business across 18 existing clients.
• Added 1 new client logo.
• Existing client expansion continued to remain the primary growth driver.
• FY26 client additions are now contributing meaningfully to revenue growth.

Note:

• Management indicated that growth remains broad-based rather than dependent on a few large customers.

CareSeed Acquisition:

Sagility completed the acquisition of CareSeed during June 2026.

Key benefits include:

• Addition of 26 new healthcare payer clients.
• Strengthened HEDIS reporting and quality management capabilities.
• Integration of Forecast and Harvest healthcare technology platforms.
• Enhanced Medicare Advantage quality solutions.
• Greater cross-selling opportunities across mid-sized healthcare payers.
• Expansion of AI-enabled quality and care-gap management solutions. 

Note:

• Management believes CareSeed significantly strengthens Sagility’s position in healthcare quality operations.

AI & Managed Services Strategy:

Management said healthcare clients are increasingly seeking partners capable of delivering measurable operational outcomes rather than traditional outsourcing.

Strategic priorities include:

• Expansion of AI-led managed services.
• Deployment of Sagility Synchrony workflow orchestration platform.
• Greater use of AI across claims management and care operations.
• End-to-end ownership of healthcare workflows.
• Outcome-based commercial engagements instead of traditional FTE-based contracts. 

Note:

• Management stated that many healthcare organisations have adopted AI but few have achieved meaningful productivity improvements, creating opportunities for Sagility’s integrated AI-led operating model.

Guidance & Outlook:

Management reaffirmed FY27 guidance:

Strategic priorities include:

• Low double-digit organic growth in constant currency.
• Adjusted EBITDA Margin: 24%–25%.
• Seasonal revenue is expected to increase during Q3 and Q4 due to U.S. Open Enrolment.
• Strong pipeline of managed services opportunities continues.
• Margin guidance maintained despite approximately 120 basis points impact from statutory wage revisions. 

Note:

• Management expects better visibility on FY27 performance after completion of the Q2 Open Enrolment preparation period.

Key Analyst Q&A Highlights:

Management clarified several important points during the earnings call:

• Revenue growth continues to come primarily from existing client expansion.
• No meaningful pricing increase contributed to revenue growth.
• AI-driven efficiency initiatives are expected to improve productivity over time.
• Healthcare outsourcing demand remains healthy despite industry cost pressures.
• The company remains actively evaluating acquisitions in clinical services, provider operations and healthcare technology.
• Net debt is expected to be fully repaid during FY27.
• Operational efficiencies and favourable currency movements are expected to offset higher wage costs. 

Note:

• Management emphasised that execution capacity is not a growth constraint; deal conversion timelines remain the primary variable.

Risk Analysis

Summary:

• Although business momentum remains strong, investors should monitor healthcare spending trends, execution of managed services opportunities and wage inflation.

Key Risks:

• Delay in conversion of large managed service deals.
• Statutory wage inflation in India.
• Foreign exchange volatility.
• U.S. healthcare regulatory changes.
• Client spending decisions.
• Integration risks relating to acquisitions.
• AI-driven pricing pressure across the outsourcing industry.

Worst Case:

• Slower healthcare outsourcing decisions combined with persistent wage inflation and weaker seasonal demand could moderate revenue growth and compress margins.

Risk Level: Medium

Company Commentary

• Management reported a strong start to FY27 supported by healthcare-focused execution.
• Existing client relationships continue to deepen.
• AI, analytics and managed services remain long-term strategic priorities.
• CareSeed strengthens healthcare quality capabilities and expands the mid-market client base.
• Management remains confident of achieving FY27 guidance despite wage inflation.
• Seasonal revenue momentum is expected to return during the second half of FY27.